ORCHIDPHAR

Orchid Pharma Limited has informed the Exchange regarding 'Issue of 14,300 Zero coupon unsecured and non-marketable Optionally Convertible Debentures of Rs.1,00,000/- each pursuant to approved Resolution plan.'.

Orchid Pharma Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of the SEBI (LODR) Regulations,2015'.

Orchid Pharma Limited has informed the Exchange regarding 'Secretarial compliance report for the year ended March 31,2020'.

Orchid Pharma Limited has informed the Exchange regarding 'Disclosure under Regulation 23(9) of SEBI (LODR) Regulations, 2015, for the half year ended on March 31, 2020'.

Orchid Pharma Limited has informed the Exchange regarding 'Disclosure of material impact of COVID-19 on the company '.

Orchid Pharma Limited has informed the Exchange regarding 'Intimation under Regulation 30(5) of SEBI (LODR) Regualtions,2015'.

Orchid Pharma Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (LODR) Regulations,2015'.

Orchid Pharma Limited has informed the Exchange regarding 'Dissolution of Shareholder, M/s Orchid Health Care Private Ltd, Promoter Group Company'.

Orchid Pharma Limited has informed the Exchange regarding 'NATIONAL COMPANY LAW APPELLATE TRIBUNAL ORDER 26.07.2019'.

Orchid Pharma Limited has informed the Exchange regarding 'Update on'the implementation of the approved resolution plan for the Corporate Debtor'.

Orchid Pharma Limited has informed the Exchange regarding 'Update on e-voting by creditors'.

Orchid Pharma Limited has informed the Exchange regarding 'Non-applicability of the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated 26th November, 2018 in respect of fund raising by issuance of Debt Securities by Large Entity '.

Orchid Pharma Limited has informed the Exchange regarding ' ANDA APPROVAL FROM US FDA FOR RISEDRONATE SODIUM TABLETS'.

Orchid Pharma Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of the SEBI (LODR) Regulations,2015'.

Orchid Pharma Limited has informed the Exchange regarding 'news paper cutting '.

Orchid Pharma Limited has informed the Exchange regarding 'DISCLOSURE UNDER REGULATION 30 OF THE SEBI(LODR) REGULATIONS,2015'.

Orchid Pharma Limited has informed the Exchange regarding 'Appointment of NSDL as the Designated Depository for the purpose of System Driven Disclosure in Securities Market'.

Orchid Pharma Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015.'.

Orchid Pharma Limited has informed the Exchange that'Orchid has received EU GMP (Good Manufacturing Practice) certification based on the inspection of the Orchid's API manufacturing facility located at SIDCO Industrial Estate, Alathur, Kancheepuram District, 603 110, Tamil Nadu, India.'.

Orchid Pharma Limited has informed the Exchange regarding 'DISCLOSURE UNDER REGULATION 30 OF THE SEBI (LODR) REGULATIONS,2015'.

Orchid Pharma Limited has informed the Exchange regarding 'FORM G -INVITATION FOR RESOLUTION PLANS '.

Orchid Pharma Limited has informed the Exchange regarding 'UPDATES-COMMITTEE OF CREDITORS MEETING'.

Orchid Pharma Limited has informed the Exchange regarding 'FORM G -INVITATION FOR RESOLUTION PLANS -INSOLVENCY AND BANKRUPTCY BOARD OF INDIA (INSOLVENCY RESOLUTION PROCESS FOR CORPORATE PERSONS) , REGULATIONS,2016'.

Orchid Pharma Limited has informed the Exchange regarding 'Resolution plans-Insolvency and Bankruptcy Board of India ( Insolvency Resolution Process for Corporate Persons) Regulations, 2016.'.

Orchid Pharma Limited has informed the Exchange regarding 'Extension of Date - Form G - Invitation for Resolution Plans-Insolvency and Bankruptcy Board of india ( Insolvancy Resolution Process for Corporate Persons) Regulations, 2016'.

Orchid Pharma Limited has informed the Exchange regarding 'Evaluation matrix for Resolution Applicants - Under Insolvency and Bankruptcy Board of India ( Insolvency Resolution process for Corporate persons ) Regulations'.

Orchid Pharma Limited has informed the Exchange regarding 'FORM G -INVITATION FOR RESOLUTION PLANS UNDER CORPORATE INSOLVENCY RESOLUTION PROCESS'.

Orchid Pharma Limited has informed the Exchange regarding 'Intimation under Regulation 30 of the SEBI ( Listing Obligations and Disclosure Requirements) Regulations, 2015.'.

Orchid Pharma Limited has informed the Exchange regarding "Receipt Of Establishment Inspection Report (EIR) From USFDA - Post Marketing Adverse Drug Experience Reporting Inspection (PADE)".

Orchid Pharma Limited has informed the Exchange regarding 'ANDA Approval From US FDA For Aripiprazole Orally Disintegrating Tablets'.

Orchid Pharma Limited has informed the Exchange regarding 'Publication For Submission Of Expression Of Interest Under Insolvency And Bankruptcy Code,2016'.

Orchid Pharma Limited has informed the Exchange regarding 'Appointment Of Resolution Professional (Rp) Under Insolvency And Bankruptcy Code,2016'.

Orchid Pharma Limited has informed the Exchange regarding 'Postponement of Committee of Creditors Meeting'.

Orchid Pharma Limited has informed the Exchange regarding 'Committee of Creditors Meeting.'.

Orchid Pharma Limited has informed the Exchange that 'Orchid has received the Establishment Inspection Report ( EIR) from US FDA based on the successful inspection of the Active Pharmaceutical Ingredients ( API) manufacturing facility located at SIDCO Industrial Estate, Alathur Kanchipuram District, Tamil Nadu, India. This facility was inspected by US FDA in May 2017.'.

Orchid Pharma Limited has informed the Exchange regarding 'Regulation 30 of the SEBI( Listing Obligations and Disclosure Requirements) Regulations, 2015.

Orchid Pharma Limited has informed the Exchange regarding 'Intimation of Initiation of CIRP to regulatory Authorities.'.

Orchid Pharma Limited has informed the Exchange regarding 'Disclosure pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements), Regulations, 2015'.

Orchid Pharma Limited has informed the Exchange regarding SETTLEMENT ORDER FROM SECURITIES AND EXCHANGE BOARD OF INDIA(SEBI) IN RESPECT OF ORCHID PHARMA LIMITED

Orchid Pharma Limited has informed the Exchange regarding Notice to shareholders Transfer of Equity Shares of the Company to Investor Education & Protection Fund ( IEPF) Suspense Account.

Orchid Pharma Limited has informed the Exchange that Orchid has received ANDA approval from US FDA for Aripiprazole Tablets USP, 2 mg , 5Mg, 10mg, 20mg, and 30mg on May 24, 2017.

Orchid Pharma Limited has informed the Exchange regarding disclosure under Regulation 30(5) of SEBI (LODR) Regulations, 2015.

Orchid Pharma Limited has informed the Exchange that ORCHID has received a Notice under Section 13(4)(a) of the SARFAESI ACT, 2002 from SICOM Limited, for the property situated at "Orchid Towers", 313, Valluvarkottam High Road, Nungambakkam, Chennai- 600 034. Based on the said Notice, SICOM Limited has taken symbolic possession on September 09, 2016. However, the Company is in an advanced stage of discussions to raise resources, so that the loan availed from SICOM can be settled expeditiously.

Orchid Pharma Limited has informed the Exchange that the Company received the Establishment inspection report (EIR) from USFDA based on the successful inspection closure for the API manufacturing facility located at Alathur, Kancheepuram District, India. The facility was inspected by USFDA in the month of August 2015.

Orchid Pharma Limited has informed the Exchange that the Company is pleased to announce that orchid received the Establishment Inspection Report (EIR) from USFDA based on the successful inspection closure for the formulation manufacturing facility located at Irungattukottai, Sriperumbudur, Kancheepuram District, India.The Facility was inspected by USFDA in the month of May 2015.

Orchid Pharma Limited has informed the Exchange that Orchid Europe Limited, UK a wholly-owned subsidiary of Orchid Pharma Limited, India has entered into a long term financial arrangement to avail up to US$ 800 million {US Dollar Eight Hundred Million) as loan with Line Trust International, Guernsey, UK. This funding will help the company explore new growth opportunities while enabling the current business achieve incremental value.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that production operations of the Company's Bulk Drugs Plant located at Alathur, Tamil Nadu have been disrupted from December 02, 2015, due to flooding at the factory premises caused by heavy rains in Chennai.The Company have now recommenced the operations in a phased manner. However, the Sterile Manufacturing Section would need to be verified for Sterility and this would take a few more days for becoming fully operational.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Orchid has received approval from the US FDA for the Abbreviated New Drug Application (ANDA) for Gemifloxacin Mesylate Tablets (320mg) with 180 days of generic drug exclusivity.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Company has received approval from the USFDA for the Abbreviated New Drug Application (ANDA) for Rivastigmine Capsules in 1.5mg, 3mg,4.5mg,6mg and Felodipine extended-release tablets in 205mg, 5mg,10mg.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors at its meeting held on July 14, 2014 has approved the delisting of the equity shares from Madras Stock Exchange Limited, pursuant to voluntary de recognision and exit of Madras Stock Exchange Limited as per the Securities and Exchange Board of India's (SEBI) circular dated May 30, 2012.